gpi 1485
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2002 (NCT00209508)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- FK506 binding protein 3BINDING AGENT
FKBP3 binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gpi 1485
- gpi 1485
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00076492 | Phase 2 | Jan 1, 2004 | Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), University of Rochester |
| NCT00090376 | Phase 2 | Dec 1, 2003 | Eisai, Symphony Capital |
| NCT00209508 | Phase 2 | Nov 1, 2002 | Eisai, Symphony Capital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 2 | 2 | 1 | 2002 |
| Symphony Capital | For profit | 2 | 0 | 1 | 2002 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2004 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2004 |
5 organizations
Page 1 / 1